wegovy
-
Report: Weight Loss Drugs Cost Significantly More for Americans than Peer Countries
A new KFF analysis compared list prices for Ozempic, Wegovy, Rybelsus and Mounjaro. It found that the U.S. has much higher list prices for these drugs than other peer countries while also having the highest rate of obesity.
-
Novo Nordisk’s Wegovy Posts Trial Data Supporting the Drug as Way to Lower Heart Risks
Novo Nordisk weight-loss drug Wegovy reduced the risk of major cardiovascular events by 20% in a large clinical trial. The company said the results support expanding the drug’s label, but the looming question is whether the data will persuade payers to cover the pricey chronic therapy.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Coalition Applauds Reintroduction of Obesity Treatment Bill, Urges Passage
The Treat and Reduce Obesity Act would expand Medicare coverage for obesity screenings, treatments and therapies like anti-obesity medications. The Health Equity Coalition for Chronic Disease came out in favor of the bill and asked for swift passage.
-
Consumer / Employer, Health Tech
LifeMD Launches GLP-1 Weight Management Program
Through LifeMD’s new weight management program, consumers can gain access to GLP-1 prescriptions like Ozempic and Wegovy, clinical support, lab testing, education and more.